Vertex Pharmaceuticals Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.05B | $2.48B | $1.70B | $1.03B | $580.6M | $1.21B | $1.53B | $1.41B |
| Net Product Revenues | $3.00B | $2.17B | $1.68B | $982.9M | $484.5M | $837.4M | — | $950.8M |
| Collaborative and Royalty Revenues | $43.9M | $317.0M | $16.7M | $48.2M | $96.1M | $374.9M | — | $460.5M |
| Cost of Revenue | $409.5M | $275.1M | $210.5M | $117.2M | $39.7M | $89.0M | $236.7M | $63.6M |
| Gross Profit | $2.64B | $2.21B | $1.49B | $914.0M | $540.9M | $1.12B | $1.29B | $1.35B |
| Gross Margin | 86.6% | 88.9% | 87.6% | 88.6% | 93.2% | 92.7% | 84.5% | 95.5% |
| Operating Expenses | ||||||||
| Research & Development | $1.42B | $1.32B | $1.05B | $995.9M | $855.5M | $882.1M | $765.9M | $707.7M |
| SG&A Expense | $557.6M | $496.1M | $432.8M | $376.6M | $305.4M | $356.2M | $432.7M | $400.7M |
| Operating Income | $635.2M | $123.2M | $9.9M | $-466.9M | $-692.4M | $-610.0M | $46.7M | $113.8M |
| Operating Margin | 20.8% | 5.0% | 0.6% | -45.3% | -119.3% | -50.3% | 3.1% | 8.1% |
| Interest Expense | $72.5M | $69.3M | — | — | — | — | $16.7M | $38.5M |
| Pretax Income | $600.2M | $-15.7M | $-67.4M | $-557.8M | $-734.9M | $-626.0M | $32.0M | $60.4M |
| Income Tax Expense | $-1.49B | $-107.3M | $16.7M | $30.4M | $7.0M | $-122.4M | $-275.0K | $19.3M |
| Net Income | $2.10B | $263.5M | $-112.1M | $-556.3M | $-738.6M | $-445.0M | $-107.0M | $29.6M |
| Net Margin | 68.8% | 10.6% | -6.6% | -54.0% | -127.2% | -36.7% | -7.0% | 2.1% |
| EPS (Basic) | $8.24 | $1.06 | $-0.46 | $-2.31 | $-3.14 | $-1.98 | $-0.50 | $0.14 |
| EPS (Diluted) | $8.09 | $1.04 | $-0.46 | $-2.31 | $-3.14 | $-1.98 | $-0.50 | $0.14 |
| Shares Outstanding (Basic) | 254.3M | 248.9M | 244.7M | 241.3M | 235.3M | 224.9M | 211.9M | 204.9M |
| Shares Outstanding (Diluted) | 259.2M | 253.2M | 244.7M | 241.3M | 235.3M | 224.9M | 215.3M | 208.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |